Description
Product Usage Information
Western Blotting: 1:1000
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody.
Protocol
Available protocols: Western Blotting
Specificity / Sensitivity
Bcr Antibody detects endogenous levels of total Bcr as well as the 210 kDa Bcr-Abl fusion protein.
Species Reactivity: Human, Mouse, Rat, Pig
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the amino-terminal sequence of human Bcr. Antibodies are purified by protein A and peptide affinity chromatography.
Background
The Bcr gene was orginally identified by its presence in the chimeric Bcr-Abl oncogene (1). The amino-terminal region of Bcr contains an oligomerization domain, a serine/threonine kinase domain, and a region that binds SH2 domains. The middle of the protein has a PH domain and a region of sequence similarity to the guanine nucleotide exchange factors for the Rho family of GTP binding proteins. The carboxy-terminal region may be involved in a GTPase activating function for the small GTP-binding protein Rac (2,3). The function of wild type Bcr in cells remains unclear. PDGF receptor may use Bcr as a downstream signaling mediator (4). Research studies have shown that the Bcr-Abl fusion results in production of a constitutively active tyrosine kinase, which causes chronic myelogenous leukemia (CML) (5). Tyr177 of Bcr is phosphorylated in the Bcr-Abl fusion protein, which plays an important role in transforming the activity of Bcr-Abl (6). Phosphorylated Tyr177 provides a docking site for Gab2 and GRB2 (7,8).
Alternate Names
ALL; BCR; BCR activator of RhoGEF and GTPase; BCR, RhoGEF and GTPase activating protein; BCR/FGFR1 chimera protein; BCR1; breakpoint cluster region; Breakpoint cluster region protein; CML; D22S11; D22S662; FGFR1/BCR chimera protein; FLJ16453; PHL; Renal carcinoma antigen NY-REN-26
